Abstract
The calcium binding protein S100 family in humans contains 21 known members, with each possessing a molecular weight between 10 and 14 kDa. These proteins are characterized by a unique helix-loop-helix EF hand motif, and often form dimers and multimers. The S100 family mainly exists in vertebrates and exerts its biological functions both inside cells as a calcium sensor/binding protein, as well as outside cells. S100A11, a member of the S100 family, may mediate signal transduction in response to internal or external stimuli and it plays various roles in different diseases such as cancers, metabolic disease, neurological diseases, and vascular calcification. In addition, it can function as chemotactic agent in inflammatory disease. In this review, we first detail the discovery of S100 proteins and their structural features, and then specifically focus on the tissue and organ expression of S100A11. We also summarize its biological activities and roles in different disease and signaling pathways, providing an overview of S100A11 research thus far.
Introduction
The S100 protein family consists of 21 members essential for vertebrate biology. While some members like S100B are well-characterized, S100A11 presents a unique biological paradox: it is ubiquitously expressed yet exhibits highly tissue-specific behaviors. Acting as a "molecular switch," S100A11 translates calcium signals into diverse biological actions. Depending on the cellular context and disease state, it can function as either a tumor suppressor or an oncogene. This paper consolidates fragmented research on S100A11’s structural features, evolutionary conservation, and its complex involvement in critical signaling pathways such as TGF-β, Wnt, and NF-κB.
Methods
This review synthesized literature spanning from the protein's discovery in 1965 to mid-2021. Key methodological approaches included:
- Structural Bioinformatics: Utilizing PDB data (structures 2LUC and 1qls) to model the 3D homodimer structure and surface charge profiles.
- Evolutionary Mapping: Constructing cladograms of CDS sequences to trace the protein's conservation across vertebrate species.
- Expression Profiling: Synthesizing data from UniProt, NCBI, and GeneCards to create comparative maps of S100A11 expression across human and mouse tissues.
Results
Structural and Evolutionary Characteristics
S100A11 is a 13 kDa protein characterized by two "EF-hand" (helix-loop-helix) motifs. It primarily functions as a homodimer, a structural hallmark shared with other members of the S100 family. Evolutionary mapping confirms that S100A11 is highly conserved across vertebrates, from fish to humans, highlighting its fundamental biological importance.
Tissue Distribution and Calcium-Dependent Relocation
In humans, S100A11 expression is highest in the skin, lungs, and kidneys, but notably low in the brain and liver. Its function is tightly linked to its cellular location, which is regulated by calcium concentrations. High calcium levels trigger S100A11 to bind with Annexin A1 and relocate to the inner cell membrane or the nucleus. In the nucleus, it can induce p21 to restrict DNA synthesis, effectively acting as a brake on cell growth.
Pathological Roles and Signaling Pathways
S100A11 exhibits a striking dichotomy in cancer. It is significantly upregulated in breast, lung, and liver cancers, where it promotes metastasis and epithelial-mesenchymal transition (EMT) via the TGF-β/SMAD axis. However, in bladder and esophageal cancers, it is downregulated, suggesting a tumor-suppressive role.
Beyond oncology, S100A11 acts as an extracellular "alarmin" or Damage-Associated Molecular Pattern (DAMP). When secreted via unconventional pathways like exosomes, it binds to RAGE receptors to trigger inflammatory cascades (e.g., RAGE/p38 MAPK) in diseases like osteoarthritis and vascular calcification. Recent evidence also links S100A11 to Non-Alcoholic Fatty Liver Disease (NAFLD), where it activates autophagic and lipogenic genes by competing for binding sites on HDAC6.
Discussion and Future Directions
Despite its potential as a diagnostic biomarker, several questions remain. The mechanism driving S100A11's switch between oncogenic and tumor-suppressive roles is still unknown. Furthermore, while its secretion via extracellular vesicles is established, the exact regulatory triggers for its release into the extracellular space require further investigation. Future research must also address the gap in metabolic disease studies and focus on developing small molecules that can specifically inhibit S100A11 without disrupting other essential S100 family proteins.
Summary updated